Pharma-Govt Collusion: Trump’s Regeneron Deal Masks Structural Drug Price Crisis, Exacerbating Inequity in U.S. Healthcare
Original framing: “Trump will unveil a deal with Regeneron to lower drug prices - AP News” — AP News (via Google News)
The original framing omits the historical role of U.S. patent laws in creating monopolies (e.g., Hatch-Waxman Act), the lack of Medicare drug price negotiation since 2003, and the disproportionate impact on Black, Indigenous, and low-income communities who face higher copays and restricted access. It also ignores global comparisons where single-payer or negotiated pricing systems achieve far lower costs, as well as the role of FDA regulatory capture in fast-tracking drugs without ensuring affordability. Indigenous knowledge systems, which view health as a communal rather than commodified right, are entirely absent.
Low structural omission detected in mainstream coverage.
The narrative is produced by AP News, a legacy outlet with deep ties to corporate and political elites, amplifying a state-corporate symbiosis that frames healthcare as a market transaction rather than a public good. The framing serves the interests of pharmaceutical lobbyists and neoliberal policymakers by normalizing public-private partnerships that privatize gains while socializing risks. It obscures the role of regulatory agencies, congressional inaction, and the revolving door between government and Big Pharma in perpetuating the crisis.
Pharmaceutical pricing is not determined by R&D costs (which are often publicly funded) but by patent monopolies and marketing expenditures, which account for 20-30% of revenue. Studies show that the U.S. pays 2-3x more for drugs than peer nations due to lack of price controls, not innovation incentives. Regeneron’s monoclonal antibodies, like many biologics, are priced at $1,500+ per dose despite marginal production costs, reflecting structural rent-seeking rather than scientific value.
The Regeneron deal exemplifies how neoliberal governance transforms public health crises into profit opportunities, with Trump’s announcement serving as a distraction from the structural rot in U.S. healthcare.